• Report Adverse Event or Product Quality Complaint
  • Global Site
AstraZeneca Medical Information
  • Prescribing Information
  • Resources
    • Congress Library
    • Our Pipeline
    • AZ Clinical Trials
    • Externally Sponsored Scientific Research
  • Connect
    • Send MIR
    • Give Feedback

Search Medical Information

American Academy of Allergy, Asthma & Immunology (AAAAI): 81st Annual Meeting - 2025

February 28 – March 3, 2025

  1. AIRSUPRA (albuterol/budesonide)
  2. FASENRA (benralizumab)
  3. TEZSPIRE (tezepelumab)

pdf

Asthma medication use before and after an asthma exacerbation: a US claims-based study

pdf

Effects on morning trough lung function with four times daily use of albuterol-budesonide versus albuterol over 1 weeks’ time: results from the DENALI study

pdf

A systematic literature review of real-world anti-interleukin-5 and anti-interleukin-5 receptor alpha treatment outcomes for hypereosinophilic syndrome: case reports and cohort studies

pdf

Patient journey to diagnosis of idiopathic hypereosinophilic syndrome (I-HES) or lymphocytic HES (L-HES) in the United States: evidence from a real-world retrospective observational cohort study

pdf

Treatment patterns in idiopathic hypereosinophilic syndrome (I-HES) or lymphocytic HES (L-HES) in the United States: a real-world retrospective observational cohort study

pdf

Two-year efficacy and safety of benralizumab for the treatment of eosinophilic granulomatosis with polyangiitis

pdf

Effect of tezepelumab on activity levels in patients with severe, uncontrolled asthma and chronic rhinosinusitis with nasal polyps in the phase 3 NAVIGATOR study

pdf

Effect of tezepelumab on fatigue in patients with severe, uncontrolled asthma and chronic rhinosinusitis with nasal polyps in the phase 3 NAVIGATOR study

html

Efficacy and safety of tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps: results from the phase 3 WAYPOINT study

pdf

Efficacy and safety of tezepelumab in adults with severe, uncontrolled asthma in Asia: results from the regional, phase 3 DIRECTION study

html

Efficacy of tezepelumab in patients with severe, uncontrolled asthma grouped by median baseline serum IL-5 and IL-13 levels: results from the phase 3 NAVIGATOR study

pdf

Substantial reduction in asthma exacerbations in patients with severe asthma with or without clinically relevant perennial allergy after 6 months of tezepelumab use: interim results from the phase 4 PASSAGE study

Need Help?

Contact Us

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

AstraZeneca Logo

This platform is provided as service to healthcare professionals by AstraZeneca Philippines, for medical educational purposes only.

©2024 AstraZeneca. All rights reserved.

PH-10554.

Last Updated 5/24

Contact Us

About Us

AstraZeneca.com

Survey Feedback

Privacy Notice

Legal Notice

Cookie Notice

Global Site

Report Adverse Event or Product Quality Complaint

Privacy NoticeLegal NoticeCookie Notice

Welcome to AstraZeneca Philippines Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the Philippines, for medical educational purposes only. AstraZeneca does not engage in the promotion of unregistered products or unapproved indications. The dissemination of this information may be subject to different medical and regulatory requirements in other countries

Are you a healthcare professional practicing in the Philippines?

No